1
|
Xiong Y, Tao K, Li T, Ou W, Zhou Y, Zhang W, Wang S, Qi R, Ji J. Resveratrol inhibits respiratory syncytial virus replication by targeting heparan sulfate proteoglycans. Food Funct 2024; 15:1948-1962. [PMID: 38270052 DOI: 10.1039/d3fo05131e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
Resveratrol, renowned as an antioxidant, also exhibits significant potential in combatting severe respiratory infections, particularly the respiratory syncytial virus (RSV). Nevertheless, the specific mechanism underlying its inhibition of RSV replication remains unexplored. Heparan sulfate proteoglycans (HSPGs) play a pivotal role as attachment factors for numerous viruses, offering a promising avenue for countering viral infections. Our research has unveiled that resveratrol effectively curbs RSV infection in a dose-dependent manner. Remarkably, resveratrol disrupts the early stages of RSV infection by engaging with HSPGs, rather than interacting with RSV surface proteins like fusion (F) protein and glycoprotein (G). Resveratrol's affinity appears to be predominantly directed towards the negatively charged sites on HSPGs, thus impeding the binding of viral receptors. In an in vivo study involving RSV-infected mice, resveratrol demonstrates its potential by ameliorating pulmonary pathology. This improvement is attributed to the inhibition of pro-inflammatory cytokine expression and a reduction in viral load within the lungs. Notably, resveratrol specifically alleviates inflammation characterized by an abundance of neutrophils in RSV-infected mice. In summation, our data first shows how resveratrol combats RSV infection through interactions with HSPGs, positioning it as a promising candidate for innovative drug development targeting RSV infections. Our study provides insight into the mechanism of resveratrol antiviral infection.
Collapse
Affiliation(s)
- Yingcai Xiong
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
- School of Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Keyu Tao
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
- School of Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Tao Li
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Weiying Ou
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Yinghui Zhou
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Wenyang Zhang
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Shouchuan Wang
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Ruogu Qi
- School of Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| | - Jianjian Ji
- Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
| |
Collapse
|
2
|
Espinar-Buitrago MDLS, Magro-López E, Vázquez-Alejo E, Muñoz-Fernández MÁ. Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection. Int J Mol Sci 2024; 25:1952. [PMID: 38396631 PMCID: PMC10887890 DOI: 10.3390/ijms25041952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/01/2024] [Accepted: 02/03/2024] [Indexed: 02/25/2024] Open
Abstract
Resistance and toxicity associated with current treatments for human cytomegalovirus (HCMV) infection highlight the need for alternatives and immunotherapy has emerged as a promising strategy. This study examined the in vitro immunological effects of co-administration of Thymosin-alpha-1 (Tα1) and polyanionic carbosilane dendrimers (PCDs) on peripheral blood mononuclear cells (PBMCs) during HCMV infection. The biocompatibility of PCDs was assessed via MTT and LDH assays. PBMCs were pre-treated with the co-administered compounds and then exposed to HCMV for 48 h. Morphological alterations in PBMCs were observed using optical microscopy and total dendritic cells (tDCs), myeloid dendritic cells (mDCs), and plasmacytoid dendritic cells (pDCs), along with CD4+/CD8+ T cells and regulatory T cells (Treg), and were characterized using multiparametric flow cytometry. The findings revealed that Tα1 + PCDs treatments increased DC activation and maturation. Furthermore, increased co-receptor expression, intracellular IFNγ production in T cells and elevated Treg functionality and reduced senescence were evident with Tα1 + G2-S24P treatment. Conversely, reduced co-receptor expression, intracellular cytokine production in T cells, lower functionality and higher senescence in Treg were observed with Tα1 + G2S16 treatment. In summary, Tα1 + PCDs treatments demonstrate synergistic effects during early HCMV infection, suggesting their use as an alternative therapeutic for preventing virus infection.
Collapse
Affiliation(s)
- María de la Sierra Espinar-Buitrago
- Section of Immunology, Immuno-Molecular Biology Laboratory (LIBM), University General Hospital Gregorio Marañon (HGUGM), 28007 Madrid, Spain; (M.d.l.S.E.-B.); (E.M.-L.); (E.V.-A.)
- Gregorio Marañon Health Research Institute (IiSGM), 28009 Madrid, Spain
- Center for Biomedical Research in Bioengineering, Biomaterials and Nanotechnology Network (CIBER-BBN), 28029 Madrid, Spain
| | - Esmeralda Magro-López
- Section of Immunology, Immuno-Molecular Biology Laboratory (LIBM), University General Hospital Gregorio Marañon (HGUGM), 28007 Madrid, Spain; (M.d.l.S.E.-B.); (E.M.-L.); (E.V.-A.)
- Gregorio Marañon Health Research Institute (IiSGM), 28009 Madrid, Spain
- Center for Biomedical Research in Bioengineering, Biomaterials and Nanotechnology Network (CIBER-BBN), 28029 Madrid, Spain
| | - Elena Vázquez-Alejo
- Section of Immunology, Immuno-Molecular Biology Laboratory (LIBM), University General Hospital Gregorio Marañon (HGUGM), 28007 Madrid, Spain; (M.d.l.S.E.-B.); (E.M.-L.); (E.V.-A.)
- Gregorio Marañon Health Research Institute (IiSGM), 28009 Madrid, Spain
- Center for Biomedical Research in Bioengineering, Biomaterials and Nanotechnology Network (CIBER-BBN), 28029 Madrid, Spain
| | - María Ángeles Muñoz-Fernández
- Section of Immunology, Immuno-Molecular Biology Laboratory (LIBM), University General Hospital Gregorio Marañon (HGUGM), 28007 Madrid, Spain; (M.d.l.S.E.-B.); (E.M.-L.); (E.V.-A.)
- Gregorio Marañon Health Research Institute (IiSGM), 28009 Madrid, Spain
- Center for Biomedical Research in Bioengineering, Biomaterials and Nanotechnology Network (CIBER-BBN), 28029 Madrid, Spain
- HIV-HGM Biobank, University General Hospital Gregorio Marañon (HGUGM), 28007 Madrid, Spain
| |
Collapse
|